Alexander Cecil
About Alexander Cecil
Alexander Cecil is a Senior Manager of API at KalVista Pharmaceuticals, Inc., where he has worked since 2021. He has extensive experience in the pharmaceutical industry, having held various roles at Karus Therapeutics Limited and completed his education at the University of Southampton.
Work at KalVista Pharmaceuticals
Alexander Cecil has been serving as the Senior Manager of API at KalVista Pharmaceuticals, Inc. since 2021. In this role, he is responsible for overseeing the development and management of active pharmaceutical ingredients. His tenure at KalVista, located in Porton Down, England, has lasted for three years, contributing to the company's focus on innovative therapies.
Previous Experience at Karus Therapeutics Limited
Prior to his current position, Alexander Cecil held multiple roles at Karus Therapeutics Limited. He worked as a Principal Scientist and Project Manager from 2015 to 2020, where he led research initiatives. He also served as a Research Team Leader from 2020 to 2021, and as a Principal Scientist from 2013 to 2015. His career at Karus spanned a total of seven years, during which he played a significant role in various projects.
Academic Background
Alexander Cecil completed his Bachelor of Science (BSc) at the University of Southampton from 1997 to 2000. He further pursued his education at the same institution, earning a Doctor of Philosophy (PhD) from 2000 to 2004. His academic training laid the foundation for his career in pharmaceutical research and development.
Early Career at University of Southampton
In the early stages of his career, Alexander Cecil worked as a Postdoctoral Research Associate at the University of Southampton from 2004 to 2005. This position allowed him to engage in advanced research projects and gain valuable experience in the field of pharmaceuticals.
Long-term Role at Karus Therapeutics Limited
From 2005 to 2013, Alexander Cecil held the position of Senior Scientist at Karus Therapeutics Limited. During this eight-year period, he contributed to various research projects, enhancing his expertise in pharmaceutical sciences and solidifying his role within the organization.